#news #biotech Sanofi walks away from Alnylam rare disease drug

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi walks away from Alnylam rare disease drug .Sanofi has turned down the chance to opt into Alnylam’s primary hyperoxaluria type 1 drug lumasiran. The French pharma’s decision gives Alnylam control of a phase 3-ready rare disease drug with an FDA breakthrough therapy designation.

from FierceBiotech: Biotech http://ift.tt/2DkL6ft